Industry Insights

  1. Future-Proofing Peptide MAM By Ensuring Scalability And Deployment 2/22/2022

    Knowledge gained through liquid-chromotography-mass spectometry can be transformed into single multiplexed assays for monitoring attributes across development, manufacturing, and release.

  2. Scaling Personalized Medicines For Flexible Aseptic Filling 2/14/2024

    Traditional aseptic filling solutions can introduce contamination and variability. Learn about Cytiva's commitment to finding innovative solutions and improving patient outcomes in the field of medicine.

  3. Understanding The Importance Of Tablet Punch Length And Cup Depth

    Learn what punch length is, how to measure it correctly, and how wear affects length and tablet consistency. 

  4. Assessing Extractables & Leachables In Parenteral Drug Products 6/8/2022

    Therapeutic complexity increases the potential risks associated with chemical composition of materials used for drug packaging. Leachables in drug or biological products are chemical compounds that originate from components that are used to store and deliver medicines. Extractables should be considered as potential leachables.

  5. Global Implications Of Zero Tariffs On Indian Pharma Exports To China 11/5/2025

    Discover the worldwide impacts of China’s zero-tariff policy on Indian pharmaceutical drugs.

  6. The 4 Technologies Poised To Transform The Pharmaceutical Supply Chain In 2025 And Beyond 12/2/2024

    These key technological advancements will significantly impact the pharma/biotech supply chain in 2025 and beyond. If you aren't implementing any of them yet, you may want to rethink your plans.

  7. The Shirokizawa Matrix: Determining The Level Of Effort, Formality, & Documentation In Cleaning Validation 12/11/2019

    This article shows how health-based exposure limits (HBEL)-based and process capability-based scales can be combined into a matrix that provides a clear visual guide for adjusting the level of effort, formality, and documentation for cleaning validation based on the level of risk.

  8. Post-Pandemic Outsourcing Demand: How Are CDMOs Responding?

    Ultimately, to serve the highly competitive biopharma and pharmaceutical markets, CDMOs must be adaptable to the culture of the company for whom they are working.

  9. RNase Control: An Overview With Market Trends 12/2/2024

    This article shares an overview of ribonuclease (RNase) control and some associated macro market research.

  10. The Value Of Orphan Drug Designation

    More than 90% of rare diseases still have no FDA-approved treatment, even though rare diseases affect more than 25 million Americans. Despite the opportunities in the orphan drug market, there are challenges that may act as barriers to entry.